T3011
AXP000080.1 · Oncolytic virus
- Platform
- HSV-1 (ICP34.5- ICP47-)
- Originator
- ImmVira Pharma
- Sponsor
- ImmVira Pharma
Names
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- conditionally replicating
- Modifications
- ICP34.5 and ICP47 deleted
- Transgenes
- IL12A, IL12B, anti-PD-1 antibody
- Route
- intratumoral, intravenous, intra arterial
- Source
- evidence
Cross-references
- NCI Thesaurus
- C175473
Approvals
No regulatory approval recorded.
Clinical trials (12)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06971614 | A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC | Recruiting | Phase 2 | 2025-06-09 | 2028-12-31 | 160 | Nonmuscle-invasive Bladder Cancer |
| NCT05756556 | T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma | Suspended | Phase 2 | 2024-06-30 | 2026-12-31 | 68 | Malignant Melanoma; Melanoma |
| NCT06283303 | A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | Unknown | Phase 1 | 2024-04-02 | 2025-11-30 | 8 | Colorectal Cancer Metastatic |
| NCT06214156 | A Clinical Study of T3011 in Subjects With Advanced Melanoma | Recruiting | Phase 1/2 | 2024-01-26 | 2026-09-30 | 42 | Advanced Melanoma |
| NCT06214143 | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | Recruiting | Phase 1/2 | 2024-01-11 | 2026-12-31 | 68 | Advanced Solid Tumors |
| NCT06200376 | A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer | Unknown | Phase 1 | 2023-09-28 | 2024-12 | 10 | Malignant Ascites |
| NCT06427291 | Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients | Unknown | Phase 1 | 2023-09-21 | 2025-12-31 | 20 | Bladder Cancer |
| NCT06200363 | A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer | Unknown | Phase 1 | 2023-09-21 | 2024-11 | 15 | Advanced Colorectal Cancer |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | Unknown | Phase 1/2 | 2022-03-01 | 2024-06 | 74 | Advanced Solid Tumor; Liver Cancer; Lung Cancer; Lymphoma; Mesothelioma of Pleura |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | Unknown | Phase 1/2 | 2021-08-10 | 2025-03 | 42 | Colorectal Cancer; Endometrial Cancer; Hepatocellular Carcinoma; NSCLC; Ovarian Cancer; Solid Tumor |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Recruiting | Phase 1/2 | 2020-09-17 | 2026-09-22 | 30 | HNSCC; Melanoma; NSCLC; Sarcoma; Solid Tumor; Squamous Cell Carcinoma |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | Unknown | Phase 1/2 | 2020-04-21 | 2023-07 | 233 | Advanced Solid Tumor; Breast Cancer; Esophagus Cancer; HNSCC; NSCLC; Non-melanoma Skin Cancer; Sarcoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41721376 | First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC. | BMC medicine | 2026 | cited by trial NCT05602792 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 35836877 | Advances in the clinical development of oncolytic viruses. | American journal of translational research | 2022 | name in abstract: T3011 |
| PMID 16517525 | Determination of acrylamide in foods by pressurized fluid extraction and liquid chromatography-tandem mass spectrometry used for a survey of Spanish cereal-based foods. | Food additives and contaminants | 2006 | name in abstract: T3011 |
Notes
Also written MVR-T3011. Dosed intratumorally, intravenously and by hepatic arterial infusion in China, Australia and the US.
How to cite
T3011 (AXP000080.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000080.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.